These findings indicate that HSD3B7 silencing significantly reduces tumorigenic potential in renal carcinoma xenograft models, supporting its role in promoting tumor growth and suggesting its potential as a therapeutic target in ccRCC. Here, HSD3B7 is linked to neoplasm.